We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE Mark
News

Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE Mark

Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE Mark
News

Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE Mark

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE Mark"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In the new era of antiviral HCV therapies, sensitive detection and measurement of HCV RNA play an important role in determining treatment duration and predicting treatment response.

“The two tests provide a holistic solution for the management of hepatitis C infection: from the confirmation of a hepatitis C infection to the prediction and assessment of treatment response,” said Paul Brown, Ph.D., Head of Roche Molecular Diagnostics. "Considering the rapidly changing hepatitis C treatment environment, we are pleased to provide two medically relevant tests on one fully automated platform. This offers clinicians the tools to manage their patients effectively and laboratories the automation and flexibility to maximize their workflow efficiency.”

COBAS AmpliPrep/COBAS TaqMan HCV Qualitative Test, v2.01 is intended for the confirmation of HCV antibody positive specimens and COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0 is intended for viral load monitoring and the prediction of virological response to antiviral therapy. Both tests are standardized with the World Health Organization (WHO) International Standard and have a limit of detection and lower limit of quantitation of 15 IU/mL. These characteristics make them medically relevant diagnostic tools in the management of hepatitis C infection.

Advertisement